Global Pediatric Neuroblastoma Treatment Market Segments 2024, Forecast To 2033
5 Mar, 2024
The pediatric neuroblastoma treatment market has shown rapid growth, increasing from $1.67 billion in 2023 to $1.84 billion in 2024, with a compound annual growth rate (CAGR) of 10.0%. This growth is attributed to advancements in treatment modalities, increased awareness, and collaborative efforts. Looking ahead to 2028, the market is expected to reach $2.58 billion, maintaining an 8.8% CAGR. The forecasted growth is linked to emerging therapies, personalized medicine, and global health initiatives.
Global Pediatric Neuroblastoma Treatment Market Key Driver
The pediatric neuroblastoma treatment market is set to grow due to an increase in new cases. Rising neuroblastoma prevalence fuels demand, leading to heightened investments in research and development by pharmaceutical entities. Improved diagnostic technology facilitates early neuroblastoma detection, with 700-800 cases reported annually in the US. Neuroblastoma constitutes 6% of childhood malignancies, primarily affecting children under five, driving market growth.
Get A Free Sample Of The Global Pediatric Neuroblastoma Treatment Market ReportGlobal Pediatric Neuroblastoma Treatment Market Segments
The pediatric neuroblastoma treatment market covered in this report is segmented –
1) By Treatment Type: Immunotherapy, Chemotherapy, Radiation Therapy, Other Treatment Types
2) By Risk Group: Low Risk, Intermediate Risk, High Risk
3) By End User: Hospitals, Specialty Clinics, Other End Users
By Geography: The regions covered in the anti inflammatory therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe,North America, South America, Middle East, and Africa. Among these regions.
North America was the largest region in the pediatric neuroblastoma treatment market in 2023. The regions covered in the pediatric neuroblastoma treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Major Pediatric Neuroblastoma Treatment Industry Players
United Therapeutics Corporation; APEIRON Biologics AG; Baxter International Inc.; Cell Ectar Biosciences Inc.; Pfizer Inc.; MacroGenics Inc.; Bayer AG; Provectus Biopharmaceuticals Inc.; Sartorius AG; Y-mAbs Therapeutics Inc.; Amgen Inc.; Eli Lilly and Company; F. Hoffmann-La Roche AG; Clarity Pharmaceuticals; CureSearch for Children's Cancer; Novartis AG; LEO Pharma A/S; UCB SA; Johnson & Johnson Services Inc.; Abbott Laboratories; AbbVie Inc.; Merck & Co. Inc.; Sanofi SA; GlaxoSmithKline plc; Bristol-Myers Squibb Company; Takeda Pharmaceutical Company Limited; Astellas Pharma Inc.; Boehringer Ingelheim International GmbH; Daiichi Sankyo Company Limited; Eisai Co. Ltd.
Get The Full Global Pediatric Neuroblastoma Treatment Market Report
AIOps Pediatric Neuroblastoma Treatment Market Overview
Pediatric neuroblastoma treatment refers to a kind of treatment for cancer or a tumor that affects the nervous system in children. Neuroblastoma is typically treated with a combination of surgery, chemotherapy, radiation therapy, immunotherapy, and targeted therapy.
Pediatric Neuroblastoma Treatment Global Market Report 2023 provides data on the global pediatric neuroblastoma treatment market such as market size, growth forecasts, segments and geographies, competitive landscape including leading competitors’ revenues, profiles and market shares. The pediatric neuroblastoma treatment market report identifies opportunities and strategies based on market trends and leading competitors’ approaches.